Argo Biopharma begins patient dosing in phase II trials of siRNA therapy BW-40202: Shanghai, China Wednesday, April 22, 2026, 15:00 Hrs [IST] Argo Biopharmaceutical Co., Ltd. (Arg ...
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced the first patient has been dosed in multiple Phase II studies of ...
Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the contribution of the lectin pathway remains unclear. Lectin pathway-dependent ...
Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant IgA antibodies in the glomerular mesangium. Now, researchers have found that ...
Promising Late-Stage Drugs Signal A New Treatment Era Delveinsight. The generalized myasthenia gravis treatment pipeline ...
Kees Smit Transfer Battle Signals New Midfield Gold RushRising Dutch Talent Attracts Elite AttentionCaught Offside report ...
Good morning, and welcome to the Akebia Therapeutics R&D Day. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Akebia website following ...
Sedona-based Alternative to Meds Center highlights Glyphosate exposure, neurological health concerns, and more used in ...
Researcher have developed a "Shallow Brain" AI model that mimics the connections between the cortex and subcortical regions, ...
GLP-1 medications may not always work for weight loss. New research suggests that around 10% of people carry genetic ...
Instead, a mental health startup shut down and open-sourced its tech.
A team of researchers in the Netherlands has proposed a new way of designing computer models of the brain—an approach that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results